What Happened with CEO Kim Jin-soo’s Stake?

On September 16, 2025, ToolGen CEO Kim Jin-soo’s stake decreased from 8.79% to 7.09% due to a donation to KAIST (85,000 shares), changes in special relationships (addition of Ms. Lee Ji-young), and stock sales and gifts (319 shares gifted to Mr. Lee Yong-min).

ToolGen: Fundamental Analysis

ToolGen is a leading company possessing CRISPR gene-editing technology, securing a stable revenue base through its patent licensing business. However, its revenue in the first half of 2025 decreased by 11.44% year-on-year to KRW 27.174 billion. High R&D investment (1,099.01% of revenue) is positive for securing future growth engines but burdens short-term profitability. The accumulated deficit of KRW 138.199 billion also suggests the need for financial soundness improvement.

  • Strengths: 397 patent portfolios, CRISPR core technology
  • Weaknesses: Revenue decline, high R&D investment burden, accumulated deficit
  • Opportunities: Growth of the gene editing market, expansion of the gene and cell therapy market
  • Threats: Intensifying competition, regulatory changes

How Will the Stake Changes Affect ToolGen’s Stock Price?

CEO Kim’s donation can be interpreted as a positive signal for the company’s future growth potential. However, the stock sales and gifts may negatively impact investor sentiment. Investors should be aware of the potential for short-term stock price volatility.

Action Plan for Investors

If considering investing in ToolGen, investors should monitor the company’s long-term performance in gene-editing technology development, clinical pipeline progress, technology transfer, and commercialization strategies. It’s crucial to continuously monitor improvements in financial soundness and changes in major shareholder stakes.